Project Grant R43DK143890
Award Date 9/15/25
Completion Date 8/31/26
Dollars Obligated $360K
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Morrisville, NC, USA
Similar Awards
- This $324,984 Project Grant was awarded on August 1, 2025 by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant recipient, Syntis Bio Inc., is developing an innovative oral therapy for treating homocystinuria, a rare metabolic disorder. The project involves optimizing a formulation that combines a protease-stable enzyme (methionine-gamma-lyase) with a...
- The Project Grant award of $324,793 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant was awarded to Nucb1 Holdings LLC on September 1, 2025 with an expected completion date of August 31, 2026. The purpose of the grant is to develop a platform technology for discovering conformation-specific, anti-protofibril monoclonal antibodies (mAbs) that target...
- This Project Grant award of $830,500.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research program) supports research investigating the role of glycosphingolipids in kidney disease associated with diabetes and obesity. The key objectives are to: Test whether inhibiting glucosylceramide synthesis in podocytes, renal tubules, or the immune system can prevent progression of kidney disease in mouse...
- This $2,638,760.00 Project Grant award was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The research aims to investigate a novel mechanism involving the metabolite rhodoquinone (RQ) and its potential role in improving mitochondrial function and mitigating metabolic diseases caused by obesity. Specifically, the project will elucidate how the RQ/fumarate...
- This federal Project Grant award of $730,498 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will support research conducted by Touro University in California to investigate the effects of fructose metabolism on the liver. The project aims to understand how the ability to convert fructose to glucose in the small intestine (gluconeogenesis) may play a protective role...
- This $1,021,719.00 federal Project Grant award was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant recipient, Emmyon, Inc., is developing a novel small molecule therapeutic (EMMY1-25) that has demonstrated the ability to promote weight loss without muscle loss and protect against dysfunction of pancreatic beta cells in mouse models of obesity and type 2...
- This federal Project Grant award of $358,039 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is supporting research by Nous Biosciences Inc. to evaluate a combination therapy of dolcanatide (a guanylate cyclase-C agonist) and atiprimod (a JAK-STAT inhibitor) for the treatment of murine colitis. The research aims to advance understanding of the pathogenesis of...
- The U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $222,500 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the Beckman Research Institute of the City of Hope. The grant supports research to understand how conjugated bile acids regulate metabolism after bariatric surgery, with the goal of developing safer and more affordable treatments for obesity and fatty liver disease. Key activities include...
- This federal Project Grant award of $350,000 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The objective is to validate the use of AVGN7 (rAAV6:SMAD7), a gene therapeutic, for treating obesity and type 2 diabetes mellitus (T2DM). The key products or services to be delivered include: (1) Demonstrating that AVGN7 can restore lean body mass and insulin...
- This $108,294 Project Grant was awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant recipient is The Medical University of South Carolina (MUSC), which will use the funding to identify novel glycomic biomarkers that can be detected in urine to monitor disease progression and predict treatment response in lupus nephritis, a serious kidney disease that affects...